Tests guselkumab in people with skin psoriasis and early joint symptoms
Tests guselkumab in adults with psoriasis and early, subclinical joint inflammation.
Key facts
- Who runs it
- Azienda Sanitaria Universitaria Friuli Centrale
- Where
- Ancona, Brunico, Ferrara, and Udine, ItalySee the 4 sites
- Trial code
- Registry title
- Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 90 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 20 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with psoriasis who have joint pain and early signs of joint inflammation on ultrasound, but no clinical arthritis yet.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Skin psoriasis: moderate to severe (PASI 10 or more), or mild (PASI 10 or less) with involvement of sensitive areas such as face, palms, soles, nails or genital area. Joint pain without clinical signs of active arthritis, dactylitis, enthesitis or inflammatory back pain. Ultrasound must show at least 2 of 4 listed signs of early joint or tendon inflammation or damage.
- Earlier treatment
- No systemic psoriasis treatment (csDMARDs, bDMARDs or tsDMARDs) in the last 6 months. No steroid injection in the last 6 months. No earlier IL-23 inhibitor treatment.
Main reasons for not taking part
- Meets CASPAR criteria for psoriatic arthritis, or has a current or earlier diagnosis of it
- Swollen joints or dactylitis on examination
- Cancer in the last 5 years, or current or suspected cancer
- Known allergy to Guselkumab or its ingredients
- Serious infection, untreated latent tuberculosis, hepatitis B or C, or HIV
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Adult ≥ 18 years of age
- Subject must be able to understand and adhere to all protocol requirements and must voluntarily sign and date an informed consent
- Subjects are willing and able to comply with procedures required in this protocol
- Presence of current from moderate to severe skin psoriasis (PASI≥10) or mild psoriasis (PASI≤10) with the involvement of sensitive area (face, palms, soles, nails, and genital area) diagnosed by a dermatologist with experience in the management of psoriatic disease
- Absence of clinical signs of active arthritis, dactylitis, enthesitis and inflammatory back pain at enrolment
- Absence of systemic treatment for psoriasis (csDMARDs and/or bDMARDs and/or tsDMARDs treatment) in the last 6 months
- The presence of peripheral arthralgia clinically suspected for subclinical PsA (definition in Appendix A)
- The Presence of at least 2 out of the following 4 sonographic lesions of subclinical inflammation or structural damage suspicious for a psoriatic musculoskeletal inflammation: (i) articular synovitis GS≥ 2 in at least 2 joints; (ii) tenosynovitis GS≥ 1 in at least 2 sites; (iii) active enthesitis in at least one site; (iv) entheseal erosion in at least one site. Ultrasound findings suggestive of subclinical PsA shall be submitted for centralized assessment and independently reviewed by two readers Sonographic Analysis Protocol The sonographic examination will preferably be performed on the same day as the clinical assessment; however, a delay of up to 72 hours from the clinical evaluation will be tolerated. The ultrasound assessment will be conducted blinded to the clinical examination and focused in a longitudinal and transverse scan of 42 regions encompassing the following: metacarpophalangeal, proximal and distal interphalangeal joints of the hands, wrists, knees, metatarsophalangeal joints, 12 entheses (Achilles, quadriceps, proximal and distal patellar, plantar aponeurosis and common extensor tendon entheses), the 2 retro-calcaneal bursae and 32 tendons (extensor digitorum tendons of the hands, flexor digitorum tendons of the hands and extensor tendon compartments of the wrist). The sites to be scanned and sonographic definitions of the lesions (i.e., synovitis, tenosynovitis, enthesitis, peritenon extensor tendon inflammation and bursitis) and damage lesions (i.e., joint erosions, entheseal erosions, enthesophytes and articular osteoproliferation) will be defined according to the OMERACT and EULAR definitions (Appendix B)
Who cannot take part
- Treatment with systemic treatment (csDMARDs or bDMARDs or tsDMARDs) and steroid injection in the 6 months previous enrolment
- Has previously received treatment with an IL-23 inhibitor
- Clinically relevant (chronic or acute) infections, including untreated (latent) tuberculosis, hepatitis B or C or HIV infections;Note: Subjects with a recent acute infection may be enrolled only after full clinical resolution of all signs and symptoms for at least 4 weeks prior to screening
- Previous or current diagnosis of PsA
- Subjects with a history of cancer within the past 5 years, as well as those with any current or suspected malignancy at the time of enrollment
- Known hypersensitivity or allergy to Guselkumab or to any component of the investigational medicinal product, including excipients
- Patients with dementia or an altered mental status, which would preclude the understanding and rendering of informed consent
- Contraindication to start a new bDMARD treatment course
- Fulfilment of CASPAR criteria for PsA
- For women of childbearing potential*: pregnancy status, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 3- months after study completion; *A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy
- Known immunodeficiency or patients immunocompromised to an extent that participation in the study would pose and unacceptable risk to the patient
- Presence of swollen joints, dactylitis or at clinical examination
Where in Italy
- Azienda Ospedaliero-Universitaria delle MarcheAncona, ItalyNot yet recruiting
- Brunico Hospital (SABES - ASDAA)Brunico, ItalyNot yet recruiting
- Università degli Studi di FerraraFerrara, ItalyNot yet recruiting
- Azienda Sanitaria Universitaria Friuli CentraleUdine, ItalyNot yet recruiting
About the trial
What the trial wants to find out
To determine whether treatment leads to clinical and ultrasonographic improvement in patients with subclinical PsA by Week 24, defined as the proportion of subclinical PsA patients who, at Week 24, achieve: (a) resolution of arthralgia, defined as VAS pain ≤ 1/10 and Tender Joint Count (TJC) ≤ 1/10, and/or (b) a measurable and significant improvement in synovio-entheseal inflammation, assessed through the UPsA Activity Score compared with baseline.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
- Plain-language title
- Tests guselkumab in people with skin psoriasis and early joint symptomsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 January 2026